NephroNovus stands at the forefront of innovative therapeutics, harnessing the latest in biochemical discoveries and cutting-edge computational techniques. Our focus is on developing a diverse portfolio of therapeutics specifically designed to reverse renal fibrosis, a key factor in the progression of chronic kidney disease. By targeting this critical pathway, NephroNovus aims to significantly improve patient outcomes and offer new hope to those suffering from this debilitating condition.Kevin Yang - CEO & Co-founder
Stay connected to everything happening at Altitude Lab.
You can trust us with your email. We don't spam.